摘要
目的:探讨肺癌患者血清中miR-23a的表达情况及其与病例临床特征的关系。方法:提取63例肺癌患者和60例健康体检人血清中总mRNA,采用qRT-PCR方法检测miR-23a的相对表达量;统计分析miR-23a的表达与肺癌侵袭转移和患者耐药的关系。结果:与健康人相比,miR-23a在肺癌患者血清中表达增高(P〈0.01);miR-23a在淋巴结转移患者血清中的表达量显著高于未转移患者(P〈0.01);miR-23a在临床I~Ⅱ期肺癌患者血清中的表达低于Ⅲ~Ⅳ期患者(P〈0.05);miR-23a在非小细胞肺癌患者中的表达高于小细胞肺癌患者(P〈0.05);miR-23a的表达量在不同年龄、性别、吸烟及不同分化程度的患者中表达差异不显著(P〉0.05)。miR-23a的表达量随患者化疗次数的增多而表达增强。结论:血清miR-23a有可能作为肺癌患者转移及耐药判断的分子标志物。
Objective To investigate the expression of miR-23a in peripheral blood and analyze its correlation with the clinic-pathological features of patients with lung cancer. Methods The level of miR-23a in peripheral blood of 63 patients with lung cancer and 60 healthy persons was detected using real-time reverse transcription-polymerase chain reaction (RT-PCR), The correlation between miR-23a level and the clinic- pathological features was analyzed. Results The expression level of miR-23a in peripheral blood of patients with lung cancer was significantly higher than that in the healthy persons (P 〈 0.01 ).The level of miR-23a was associated with TNM stage (P 〈 0.05), Lymphatic metastasis (P 〈 0.01) and the number of chemotherapy (P 〈 0.01 ). Conclusion The miR-23a level in peripheral blood might be a molecular marker for the diagnosis and prognosis of patients with lung cancer.
出处
《实用医学杂志》
CAS
北大核心
2015年第14期2297-2300,共4页
The Journal of Practical Medicine
基金
江西省科技厅基金项目(编号:20142BAB205101)
江西省教育厅资助项目(编号:GJJ14684)